Gut microbiota in multiple sclerosis: Possible influence of immunomodulators

Brandi L. Cantarel, Emmanuelle Waubant, Christel Chehoud, Justin Kuczynski, Todd Z. Desantis, Janet Warrington, Arun Venkatesan, Claire M. Fraser, Ellen M. Mowry

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Objectives: Differences in gut bacteria have been described in several autoimmune disorders. In this exploratory pilot study,we compared gut bacteria in patients with multiple sclerosis and healthy controls and evaluated the influence of glatiramer acetate and vitamin D treatment on the microbiota. Methods: Subjects were otherwise healthy white women with or without relapsing-remitting multiple sclerosis who were vitamin D insufficient. Patients with multiple sclerosis were untreated or were receiving glatiramer acetate. Subjects collected stool at baseline and after 90 days of vitamin D3 (5000 IU/d) supplementation. The abundance of operational taxonomic units was evaluated by hybridization of 16S rRNA to a DNA microarray. Results: While there was overlap of gut bacterial communities, the abundance of some operational taxonomic units, including Faecalibacterium, was lower in patients with multiple sclerosis. Glatiramer acetate-treated patients with multiple sclerosis showed differences in community composition compared with untreated subjects, including Bacteroidaceae, Faecalibacterium, Ruminococcus, Lactobacillaceae, Clostridium, and other Clostridiales. Compared with the other groups, untreated patients with multiple sclerosis had an increase in the Akkermansia, Faecalibacterium, and Coprococcus genera after vitamin D supplementation. Conclusions: While overall bacterial communities were similar, specific operational taxonomic units differed between healthy controls and patientswith multiple sclerosis. Glatiramer acetate and vitamin D supplementation were associated with differences or changes in the microbiota. This study was exploratory, and larger studies are needed to confirm these preliminary results.

Original languageEnglish (US)
Pages (from-to)729-734
Number of pages6
JournalJournal of Investigative Medicine
Volume63
Issue number5
DOIs
StatePublished - Jun 3 2015

Fingerprint

Immunologic Factors
Vitamin D
Multiple Sclerosis
Bacteria
Microbiota
Clostridium
Lactobacillaceae
Bacteroidaceae
Cholecalciferol
Microarrays
Ruminococcus
Relapsing-Remitting Multiple Sclerosis
Oligonucleotide Array Sequence Analysis
Gastrointestinal Microbiome
Glatiramer Acetate
DNA
Chemical analysis
Faecalibacterium

Keywords

  • autoimmunity
  • glatiramer acetate
  • gut microbiome
  • multiple sclerosis
  • vitamin D

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Cantarel, B. L., Waubant, E., Chehoud, C., Kuczynski, J., Desantis, T. Z., Warrington, J., ... Mowry, E. M. (2015). Gut microbiota in multiple sclerosis: Possible influence of immunomodulators. Journal of Investigative Medicine, 63(5), 729-734. https://doi.org/10.1097/JIM.0000000000000192

Gut microbiota in multiple sclerosis : Possible influence of immunomodulators. / Cantarel, Brandi L.; Waubant, Emmanuelle; Chehoud, Christel; Kuczynski, Justin; Desantis, Todd Z.; Warrington, Janet; Venkatesan, Arun; Fraser, Claire M.; Mowry, Ellen M.

In: Journal of Investigative Medicine, Vol. 63, No. 5, 03.06.2015, p. 729-734.

Research output: Contribution to journalArticle

Cantarel, BL, Waubant, E, Chehoud, C, Kuczynski, J, Desantis, TZ, Warrington, J, Venkatesan, A, Fraser, CM & Mowry, EM 2015, 'Gut microbiota in multiple sclerosis: Possible influence of immunomodulators', Journal of Investigative Medicine, vol. 63, no. 5, pp. 729-734. https://doi.org/10.1097/JIM.0000000000000192
Cantarel, Brandi L. ; Waubant, Emmanuelle ; Chehoud, Christel ; Kuczynski, Justin ; Desantis, Todd Z. ; Warrington, Janet ; Venkatesan, Arun ; Fraser, Claire M. ; Mowry, Ellen M. / Gut microbiota in multiple sclerosis : Possible influence of immunomodulators. In: Journal of Investigative Medicine. 2015 ; Vol. 63, No. 5. pp. 729-734.
@article{bd907546edf1449889c845b5d2ee5926,
title = "Gut microbiota in multiple sclerosis: Possible influence of immunomodulators",
abstract = "Objectives: Differences in gut bacteria have been described in several autoimmune disorders. In this exploratory pilot study,we compared gut bacteria in patients with multiple sclerosis and healthy controls and evaluated the influence of glatiramer acetate and vitamin D treatment on the microbiota. Methods: Subjects were otherwise healthy white women with or without relapsing-remitting multiple sclerosis who were vitamin D insufficient. Patients with multiple sclerosis were untreated or were receiving glatiramer acetate. Subjects collected stool at baseline and after 90 days of vitamin D3 (5000 IU/d) supplementation. The abundance of operational taxonomic units was evaluated by hybridization of 16S rRNA to a DNA microarray. Results: While there was overlap of gut bacterial communities, the abundance of some operational taxonomic units, including Faecalibacterium, was lower in patients with multiple sclerosis. Glatiramer acetate-treated patients with multiple sclerosis showed differences in community composition compared with untreated subjects, including Bacteroidaceae, Faecalibacterium, Ruminococcus, Lactobacillaceae, Clostridium, and other Clostridiales. Compared with the other groups, untreated patients with multiple sclerosis had an increase in the Akkermansia, Faecalibacterium, and Coprococcus genera after vitamin D supplementation. Conclusions: While overall bacterial communities were similar, specific operational taxonomic units differed between healthy controls and patientswith multiple sclerosis. Glatiramer acetate and vitamin D supplementation were associated with differences or changes in the microbiota. This study was exploratory, and larger studies are needed to confirm these preliminary results.",
keywords = "autoimmunity, glatiramer acetate, gut microbiome, multiple sclerosis, vitamin D",
author = "Cantarel, {Brandi L.} and Emmanuelle Waubant and Christel Chehoud and Justin Kuczynski and Desantis, {Todd Z.} and Janet Warrington and Arun Venkatesan and Fraser, {Claire M.} and Mowry, {Ellen M.}",
year = "2015",
month = "6",
day = "3",
doi = "10.1097/JIM.0000000000000192",
language = "English (US)",
volume = "63",
pages = "729--734",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Gut microbiota in multiple sclerosis

T2 - Possible influence of immunomodulators

AU - Cantarel, Brandi L.

AU - Waubant, Emmanuelle

AU - Chehoud, Christel

AU - Kuczynski, Justin

AU - Desantis, Todd Z.

AU - Warrington, Janet

AU - Venkatesan, Arun

AU - Fraser, Claire M.

AU - Mowry, Ellen M.

PY - 2015/6/3

Y1 - 2015/6/3

N2 - Objectives: Differences in gut bacteria have been described in several autoimmune disorders. In this exploratory pilot study,we compared gut bacteria in patients with multiple sclerosis and healthy controls and evaluated the influence of glatiramer acetate and vitamin D treatment on the microbiota. Methods: Subjects were otherwise healthy white women with or without relapsing-remitting multiple sclerosis who were vitamin D insufficient. Patients with multiple sclerosis were untreated or were receiving glatiramer acetate. Subjects collected stool at baseline and after 90 days of vitamin D3 (5000 IU/d) supplementation. The abundance of operational taxonomic units was evaluated by hybridization of 16S rRNA to a DNA microarray. Results: While there was overlap of gut bacterial communities, the abundance of some operational taxonomic units, including Faecalibacterium, was lower in patients with multiple sclerosis. Glatiramer acetate-treated patients with multiple sclerosis showed differences in community composition compared with untreated subjects, including Bacteroidaceae, Faecalibacterium, Ruminococcus, Lactobacillaceae, Clostridium, and other Clostridiales. Compared with the other groups, untreated patients with multiple sclerosis had an increase in the Akkermansia, Faecalibacterium, and Coprococcus genera after vitamin D supplementation. Conclusions: While overall bacterial communities were similar, specific operational taxonomic units differed between healthy controls and patientswith multiple sclerosis. Glatiramer acetate and vitamin D supplementation were associated with differences or changes in the microbiota. This study was exploratory, and larger studies are needed to confirm these preliminary results.

AB - Objectives: Differences in gut bacteria have been described in several autoimmune disorders. In this exploratory pilot study,we compared gut bacteria in patients with multiple sclerosis and healthy controls and evaluated the influence of glatiramer acetate and vitamin D treatment on the microbiota. Methods: Subjects were otherwise healthy white women with or without relapsing-remitting multiple sclerosis who were vitamin D insufficient. Patients with multiple sclerosis were untreated or were receiving glatiramer acetate. Subjects collected stool at baseline and after 90 days of vitamin D3 (5000 IU/d) supplementation. The abundance of operational taxonomic units was evaluated by hybridization of 16S rRNA to a DNA microarray. Results: While there was overlap of gut bacterial communities, the abundance of some operational taxonomic units, including Faecalibacterium, was lower in patients with multiple sclerosis. Glatiramer acetate-treated patients with multiple sclerosis showed differences in community composition compared with untreated subjects, including Bacteroidaceae, Faecalibacterium, Ruminococcus, Lactobacillaceae, Clostridium, and other Clostridiales. Compared with the other groups, untreated patients with multiple sclerosis had an increase in the Akkermansia, Faecalibacterium, and Coprococcus genera after vitamin D supplementation. Conclusions: While overall bacterial communities were similar, specific operational taxonomic units differed between healthy controls and patientswith multiple sclerosis. Glatiramer acetate and vitamin D supplementation were associated with differences or changes in the microbiota. This study was exploratory, and larger studies are needed to confirm these preliminary results.

KW - autoimmunity

KW - glatiramer acetate

KW - gut microbiome

KW - multiple sclerosis

KW - vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84930361344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930361344&partnerID=8YFLogxK

U2 - 10.1097/JIM.0000000000000192

DO - 10.1097/JIM.0000000000000192

M3 - Article

C2 - 25775034

AN - SCOPUS:84930361344

VL - 63

SP - 729

EP - 734

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 5

ER -